Advertisement

Clinical Pharmacokinetics, Safety and Exploratory Efficacy Study of a Topical Bactericidal VB-1953: Analysis of Single and Multiple Doses in a Phase I Trial in Acne Vulgaris Subjects

  • Shilpi JainEmail author
  • Vishal Yadav
  • Neal Bhatia
Original Research Article
  • 15 Downloads

Abstract

Background and Objective

Cutibacterium acnes is a key pathogenic factor in the development of acne vulgaris. Topical and oral antibiotics play a pivotal role in effective management of the disease. The emergence of resistance to the currently available antibiotics poses a serious set-back to this algorithm, and the reduced arsenal can diminish the efficacy of treatment. A novel formulation of VB-1953 (2%) topical gel has been developed with dual mechanism of action and bactericidal activity, unlike the currently approved antibiotics, which are bacteriostatic agents, targeting acne vulgaris. The objective was to check the clinical pharmacokinetics, safety and tolerability of single and multiple doses of VB-1953 in adult subjects with facial acne vulgaris, when applied twice daily (every 12 h) for about 15 days starting from Day 1, morning dose until Day 15, morning dose.

Methods

This was a Phase 1 open-label study of VB-1953 for evaluation of pharmacokinetics, safety, tolerability and exploratory efficacy in otherwise healthy adult patients with moderate-to-severe facial acne vulgaris. The 12 subjects (aged 18–45 years) enrolled for the study applied VB-1953 (2%) gel twice daily for 15 days on the entire face every 12 h starting from Day 1 morning to Day 15 morning. Pharmacokinetic assessment was evaluated by sequential blood collection and safety was measured by assessments of local skin reactions (LSRs).

Results

Plasma concentrations of VB-1953 indicate a low systemic exposure. By Day 2, steady-state was achieved and by Day 15 maximum plasma concentration (Cmax) was 0.4640 ng/mL indicating about twofold increase upon multiple dosing. Changes in safety parameters (vital signs, electrocardiogram, physical examinations, hematology, chemistry, urinalysis) were clinically insignificant.

Conclusion

VB-1953 topical gel appears to be safe for use in adults with facial acne vulgaris and may offer new advances as a topical antibiotic agent for the disease.

Notes

Author Contribution

All the authors contributed to study conception and design, drafting and revising the manuscript. NB was the Principal Investigator of the Phase-I study including safety, tolerability, pharmacokinetics and exploratory efficacy. NB and SJ participated in statistical analysis. All the authors reviewed and approved the final manuscript.

Compliance with Ethical Standards

Funding

This study was funded by Vyome Therapeutics Limited.

Conflict of interest

SJ and VY are employees of Vyome Therapeutics Ltd. NB is a consultant to Vyome Therapeutics Limited and has no conflict of interest.

Ethical approval

All procedures performed in the study were in accordance with the ethical standards of the principles of Good Clinical Practice (GCP) and with the 1964 Helsinki Declaration and its later amendments. The central Institutional Review Board (IRB), Quorum Review IRB, Seattle, USA approval was sought at the site for the initial protocol and for protocol amendments. Written informed consent was obtained from all individual participants included in the study before commencing any study-related procedures.

Supplementary material

40261_2019_883_MOESM1_ESM.pdf (152 kb)
Supplementary material 1 (PDF 151 kb)

References

  1. 1.
    Titus S, Hodge J. Diagnosis and treatment of acne. Am Fam Physician. 2012;86(8):734–40.PubMedGoogle Scholar
  2. 2.
    Tan JK, Bhate K. A global perspective on the epidemiology of acne. Br J Dermatol. 2015;172(Suppl 1):3–12.CrossRefGoogle Scholar
  3. 3.
    Cunliffe WJ, Clayden AD, Gould D, Simpson NB. Acne vulgaris—its aetiology and treatment. A review. Clin Exp Dermatol. 1981;6(5):461–9.CrossRefGoogle Scholar
  4. 4.
    Nast A, Dreno B, Bettoli V, Degitz K, Erdmann R, Finlay AY, et al. European evidence based (S3) guidelines for the treatment of acne. J Eur Acad Dermatol Venereol. 2012;26(Suppl 1):1–29.CrossRefGoogle Scholar
  5. 5.
    Thiboutot D, Gollnick H, Bettoli V, Dréno B, Kang S, Leyden JJ, et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol. 2009;60(5 Suppl):S1–50.CrossRefGoogle Scholar
  6. 6.
    Aslam I, Fleischer A, Feldman S. Emerging drugs for the treatment of acne. Expert Opin Emerg Drugs. 2015;20(1):91–101.CrossRefGoogle Scholar
  7. 7.
    Leyden JJ, McGinley KJ, Cavalieri S, Webster GF, Mills OH, Kligman AM. Propionibacterium acnes resistance to antibiotics in acne patients. J Am Acad Dermatol. 1983;8(1):41–5.CrossRefGoogle Scholar
  8. 8.
    Simonart T, Dramaix M. Treatment of acne with topical antibiotics: lessons from clinical studies. Br J Dermatol. 2005;153(2):395–403.CrossRefGoogle Scholar
  9. 9.
    Hooper DC. Emerging mechanisms of fluoroquinolone resistance. Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis. 2001;7:337–41.CrossRefGoogle Scholar
  10. 10.
    Kampranis SC, Maxwell A. The DNA gyrase-quinolone complex. ATP hydrolysis and the mechanism of DNA cleavage. J Biol Chem. 1998;273(35):22615–26.CrossRefGoogle Scholar
  11. 11.
    Kurokawa I, Akamatsu H, Nishijima S, Asada Y, Kawabata S. Clinical and bacteriologic evaluation of OPC-7251 in patients with acne: a double-blind group comparison study versus cream base. J Am Acad Dermatol. 1991;25(4):674–81.CrossRefGoogle Scholar
  12. 12.
    Schöfer H, Göllner A, Kusche W, Schwantes U. Effectiveness and tolerance of topical nadifloxacin in the therapy of acne vulgaris (grade I-II): results of a non-interventional trial in 555 patients. J Appl Res. 2009;9(3):44–51.Google Scholar
  13. 13.
    Plewig G, Holland KT, Nenoff P. Clinical and bacteriological evaluation of nadifloxacin 1% cream in patients with acne vulgaris: a double-blind, phase III comparison study versus erythromycin 2% cream. Eur J Dermatol. 2006;16(1):48–55.PubMedGoogle Scholar
  14. 14.
    Sinha M, Sadhasivam S, Bhattacharyya A, Jain S, Ghosh S, Arndt KA, et al. Antibiotic-resistant acne: getting under the skin. Semin Cutan Med Surg. 2016;35(2):62–7.CrossRefGoogle Scholar
  15. 15.
    Tan HH. Topical antibacterial treatments for acne vulgaris: comparative review and guide to selection. Am J Clin Dermatol. 2004;5(2):79–84.CrossRefGoogle Scholar
  16. 16.
    Sadhasivam S, Sinha M, Saini S, Kaur SP, Gupta T, Sengupta S, et al. Heterogeneity and antibiotic resistance in Propionibacterium acnes isolates and its therapeutic implications: blurring the lines between commensal and pathogenic phylotypes. Dermatol Ther. 2016;29(6):451–4.CrossRefGoogle Scholar
  17. 17.
    Ghosh S, Sinha M, Bhattacharyya A, Sadhasivam S, Megha J, Reddy S, et al. A rationally designed multifunctional antibiotic for the treatment of drug-resistant acne. J Invest Dermatol. 2018;138(6):1400–8.CrossRefGoogle Scholar
  18. 18.
    Batra R, Sadhasivam S, Saini S, Gupta S, Jain S, Secci A, et al. A clinical study to test the efficacy of VB-1953 in clindamycin non-responder acne patients with antibiotic-resistant P. acnes. J Invest Dermatol. 2019;139(5):S104.  https://doi.org/10.1016/j.jid.2019.03.684.CrossRefGoogle Scholar
  19. 19.
    Guidance for industry: Acne vulgaris: developing drugs for treatment, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 2005.Google Scholar
  20. 20.
    Jung JY, Kwon HH, Yeom KB, Yoon MY, Suh DH. Clinical and histological evaluation of 1% nadifloxacin cream in the treatment of acne vulgaris in Korean patients. Int J Dermatol. 2011;50(3):350–7.CrossRefGoogle Scholar
  21. 21.
    Akhavan A, Bershad S. Topical acne drugs: review of clinical properties, systemic exposure and safety. Am J Clin Dermatol. 2003;4(7):473–92.CrossRefGoogle Scholar
  22. 22.
    ACZONE® (dapsone) Gel, 7.5%, for topical use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207154s003lbl.pdf. Accessed 05 July 2019.
  23. 23.
    DIFFERIN® (adapalene) Gel, 0.3%. https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021753lbl.pdf. Accessed 05 July 2019.
  24. 24.
    BenzaClin® topical Gel (clindamycin - benzoyl peroxide gel). https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050756s037lbl.pdf. Accessed 05 July 2019.
  25. 25.
    Ziana™ (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel. https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/050802lbl.pdf. Accessed 05 July 2019.
  26. 26.
    van Hoogdalem EJ. Transdermal absorption of topical anti-acne agents in man; review of clinical pharmacokinetic data. J Eur Acad Dermatol Venereol. 1998;11(Suppl 1):S13–9 (discussion S28-9).CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Vyome Therapeutics LimitedDelhiIndia
  2. 2.Therapeutics Clinical ResearchSan DiegoUSA

Personalised recommendations